Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models

doi:10.1038/s41422-020-00450-0

KIB OpenIR

	Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
	Wang,Gan ; Yang,Meng-Li ; Duan,Zi-Lei ; Liu,Feng-Liang ; Jin,Lin ; Long,Cheng-Bo ; Zhang,Min ; Tang,Xiao-Peng ; Xu,Ling ; Li,Ying-Chang ; Kamau,Peter Muiruri ; Yang,Lian ; Liu,Hong-Qi ; Xu,Jing-Wen ; Chen,Jie-Kai ; Zheng,Yong-Tang ; Peng,Xiao-Zhong ; Lai,Ren
	2021
发表期刊	CELL RESEARCH
ISSN	1001-0602
卷号	31 期号:1 页码:17-24
摘要	Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic worldwide. Currently, however, no effective drug or vaccine is available to treat or prevent the resulting coronavirus disease 2019 (COVID-19). Here, we report our discovery of a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, based on virtual screening of the FDA-approved peptide drug library combined with in vitro and in vivo functional antiviral assays. Our results showed that dalbavancin directly binds to human angiotensin-converting enzyme 2 (ACE2) with high affinity, thereby blocking its interaction with the SARS-CoV-2 spike protein. Furthermore, dalbavancin effectively prevents SARS-CoV-2 replication in Vero E6 cells with an EC50 of similar to 12 nM. In both mouse and rhesus macaque models, viral replication and histopathological injuries caused by SARS-CoV-2 infection are significantly inhibited by dalbavancin administration. Given its high safety and long plasma half-life (8-10 days) shown in previous clinical trials, our data indicate that dalbavancin is a promising anti-COVID-19 drug candidate.
关键词	SARS ENTRY MERS
DOI	10.1038/s41422-020-00450-0
WOS记录号	WOS:000595392700004
引用统计	被引频次：76[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.kib.ac.cn/handle/151853/73006
专题	中国科学院昆明植物研究所
作者单位	1.Chinese Acad Sci, Kunming Primate Res Ctr, Key Lab Anim Models & Human Dis Mech,Natl Resourc, Key Lab Bioact Peptides Yunnan Prov,KIZ CUHK Join, Kunming 650107, Yunnan, Peoples R China 2.Kunming Inst Zool, Natl Res Facil Phenotyp & Genet Anal Model Anim P, Kunming 650107, Yunnan, Peoples R China 3.Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Kunming 650031, Yunnan, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 5.Chinese Acad Sci, Sino African Joint Res Ctr, Wuhan 430074, Hubei, Peoples R China 6.Chinese Acad Sci, Kunming Inst Bot, Kunming 650201, Yunnan, Peoples R China 7.Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510530, Guangdong, Peoples R China 8.Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming Inst Zool, Kunming 650107, Yunnan, Peoples R China 9.Chinese Acad Sci, Inst Drug Discovery & Dev, Shanghai 201203, Peoples R China
推荐引用方式 GB/T 7714	Wang,Gan,Yang,Meng-Li,Duan,Zi-Lei,et al. Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models[J]. CELL RESEARCH,2021,31(1):17-24.
APA	Wang,Gan.,Yang,Meng-Li.,Duan,Zi-Lei.,Liu,Feng-Liang.,Jin,Lin.,...&Lai,Ren.(2021).Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models.CELL RESEARCH,31(1),17-24.
MLA	Wang,Gan,et al."Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models".CELL RESEARCH 31.1(2021):17-24.